Record overview
Status and phase
Status: ACTIVE_NOT_RECRUITING
Phase: PHASE1, PHASE2
Sponsor: Merck Sharp & Dohme LLC
Condition: Bladder Cancer
NCT06305767
A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)
Public trial-level signal summary for this oncology Phase 2 record.
Signal summary
Public flags
Status signal: Low Signal
Timeline signals: long_recruitment_duration_signal
Results signal: Low Signal
Operational burden: large_enrollment_target_signal
Stopped reason
Context when available
No stop reason available in the current public record.